Carisma Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Carisma Therapeutics

14/05/2025 10:24

Carisma Therapeutics Inc CARM.OQ reported a quarterly adjusted loss of 22 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -46 cents.  The lone analyst forecast for the quarter was for a loss of 12 cents per share.

Revenue rose 9.8% to $3.73 million from a year ago; analysts expected $3.75 million.

Carisma Therapeutics Inc's reported EPS for the quarter was a loss of 22 cents​.

Carisma Therapeutics Inc shares had fallen by 40.1% this quarter and lost 55.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 33.3% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "hold."

Wall Street's median 12-month price target for Carisma Therapeutics Inc is $1.00

This summary was machine generated from LSEG data May 14 at 09:23 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.12
-0.22
Missed
Dec. 31 2024
-0.16
-0.42
Missed
Sep. 30 2024
-0.26
-0.31
Missed
Jun. 30 2024
-0.30
-0.27
Beat